Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Thiogenesis Therapeutics Corp

TTI.V ✓ COMPLIANT ☆ Track — members

TSX Venture · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$0.37

▲ +2.00%

Market Cap $25.88M · Vol 30.00K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$25.88M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

36.36

Momentum

Beta

0.55

vs Market

52W High

$0.60

37.38% below

52W Low

$0.32

15.89% above

Volume

30.00K

Avg 16.65K

P/B

58.66

Price-to-book

ROE

N/A

Return on equity

Free Float

85.91%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Thiogenesis Therapeutics Corp (TTI.V) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TTI.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-7.27%

-8.93%

-7.27%

YTD

-21.54%

-36.25%

-22.76%

+131.82%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-5,411,017.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-256.14% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	58.66
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	69.98M

Technical Indicators

50-Day SMA	$0.40
200-Day SMA	$0.42
RSI (14)	36.36
Beta	0.55
52-Week High	$0.60
52-Week Low	$0.32

Volume Today	30.00K
Avg Daily Volume (30D)	16.65K
Relative Volume	1.80x
Volatility (10D)	53.52
Volatility (30D)	51.14
Free Float	85.91%

Analyst Consensus

N/A

Current Price $0.37

Mean Target N/A

52W Low$0.32 52W High$0.60

Current

Target

$0.32 $0.60

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX Venture

FIGIBBG00NSLMCF5

ISINCA88410L1022

CountryCanada

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.09% ONC BeOne Medicines AG +1.44% RVMD Revolution Medicines Inc -1.07% 068270.KS Celltrion Inc -0.93% ABVX Abivax SA -2.75%

Company Profile

Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.